BRD4 and cancer: Despite a greater than 10‐fold loss in binary binding affinity for Brd4, macroPROTAC‐1 exhibits rapid and potent intracellular degradation of Brd4, and cytotoxicity in BET‐sensitive cancer cell lines that are comparable to MZ1.